inVentiv and ACRES partner to create a global research platform for clinical trials

11 July 2014

Two bodies are partnering to fast-track the development of a global system to support responsible conduct of clinical trials and operate them at high standards of safety, quality and efficiency.

inVentiv Clinical Trial Recruitment Solutions (iCTRS), which accelerates trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit organization that operates in the public interest for enhancing quality, safety, integrity and effectiveness in drug development and health research, have teamed up for this global clinical research platform.

Lack of uniform standards

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK